Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL0137 Combined With Ipilimumab and Nivolumab in Advanced Melanoma
NCT05498792Phase 1Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cbl0137 in melanoma (3 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Initial assessment of safety and tolerability at 28 days. Started Nov 2022; status: recruiting.
02
Drugs
cbl0137
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05498792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498792.